非布索坦在治疗痛风这方面疗效如何？

How effective is (Febuxostat) in treating gout? Let’s find out below. Animal experiments show that compared with allopurinol, febuxostat is 10 to 30 times more powerful. The structure of Febuxostat (Febuxostat) is a non-purine analog, so it has selective inhibition on xanthine oxidase and has little effect on other enzymes involved in purine and pyrimidine metabolism. Allopurinol is a purine analogue, which can affect the activity of other enzymes involved in purine and pyrimidine metabolism in the body, and is prone to some adverse reactions. The specificity of the inhibitory effect of Febuxostat (Febuxostat) can avoid these possible adverse reactions. Febuxostat is completely absorbed after oral administration, with a bioavailability of approximately 85%, a peak time of approximately 1 hour, and a half-life of 5 to 8 hours. Food and antacids have no significant effect on the absorption of febuxostat.

Research results show that long-term use of febuxostat (febuxostat) can maintain long-term blood uric acid at ≤6.0 mg/dl in most patients. Mild to moderate impairment of renal function has no significant impact on the pharmacodynamics and pharmacokinetics of febuxostat. Therefore, the uric acid-lowering effect of febuxostat is no different from that of patients with normal renal function, and its safety is good. In short, febuxostat (febuxostat) has a better uric acid-lowering effect than allopurinol without serious adverse reactions, and has good clinical application prospects.

A multicenter, double-blind, randomized phase II clinical study evaluated the safety and efficacy of febuxostat (febuxostat) in gout. A total of 136 male and 17 female gout patients were randomized to receive placebo or this product (40, 80 or 120mg/d). After 4 weeks, tests found that the serum uric acid concentration of patients in each dose group of febuxostat (febuxostat) was significantly lower than before treatment. The average reductions in each group from low to high doses were 37%, 44% and 59% respectively, while patients in the placebo group only saw a 2% reduction. The vast majority of patients persisted in completing the trial. The incidence of adverse reactions was similar between this product and the placebo group, and most of these adverse reactions were mild.

The above is the efficacy of Febuxostat (Febuxostat) provided by our medical companion tour in the treatment of gout. From this point of view, the therapeutic effect of (Febuxostat) is still very good.

Related hot article recommendations: